BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1811 related articles for article (PubMed ID: 17476695)

  • 1. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
    Choi SS; Diehl AM
    Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2008 Feb; 47(2):625-35. PubMed ID: 18000880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
    Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes.
    Larter CZ; Yeh MM; Williams J; Bell-Anderson KS; Farrell GC
    J Hepatol; 2008 Sep; 49(3):407-16. PubMed ID: 18534710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.
    Kamada Y; Matsumoto H; Tamura S; Fukushima J; Kiso S; Fukui K; Igura T; Maeda N; Kihara S; Funahashi T; Matsuzawa Y; Shimomura I; Hayashi N
    J Hepatol; 2007 Oct; 47(4):556-64. PubMed ID: 17459514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
    Salamone F; Galvano F; Cappello F; Mangiameli A; Barbagallo I; Li Volti G
    Transl Res; 2012 Jun; 159(6):477-86. PubMed ID: 22633099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
    Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
    J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.
    Kirsch R; Clarkson V; Verdonk RC; Marais AD; Shephard EG; Ryffel B; de la M Hall P
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):174-82. PubMed ID: 16706830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
    Tomita K; Oike Y; Teratani T; Taguchi T; Noguchi M; Suzuki T; Mizutani A; Yokoyama H; Irie R; Sumimoto H; Takayanagi A; Miyashita K; Akao M; Tabata M; Tamiya G; Ohkura T; Hibi T
    Hepatology; 2008 Aug; 48(2):458-73. PubMed ID: 18666257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):973-83. PubMed ID: 19307976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
    Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
    J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.